Merkel carcinoma (CCM) is aggressive skin cancer, with, at the metastatic stage inoperable, only one effective therapeutic option currently available (Avelumab). However, the use of this treatment provides a sustainable objective response in only 25 % of patients underlining the need to identify new therapeutic strategies in this area. CD56 has recently been identified as a membrane target frequently expressed by CCMs. In this context, the relevance of targeting CD56 as a therapeutic option in the JCC was assessed. To do this, a human antibody, recognising this target of interest, was bioconjugated to MMAE by McSAF Inside® technology, a technology developed by McSAF for the generation of new biomedicines. The cytotoxicity of this antibody-drug conjugate (ADCITMER), named ADCITMER, has been demonstrated in vitro and in vivo in a mouse model of xenograft using a human line of CCM (patented technology). The objective of this project is to obtain an extensive characterisation of the ADCITMER product allowing the completion of a Phase I study. — An assessment of the intrinsic properties of the biomedicine, – A characterisation of the performance of the product in the indication CCM, – The evaluation of this biomedicine in other indications in oncology, in particular through the establishment of a European consortium via Studium. The results gen